Genomic-based tools for the risk assessment, management, and prevention of type 2 diabetes

Katherine A Johansen Taber, Barry D DickinsonDepartment of Science and Biotechnology, American Medical Association, Chicago, IL, USAAbstract: Type 2 diabetes (T2D) is a common and serious disorder and is a significant risk factor for the development of cardiovascular disease, neuropathy, nephropath...

Full description

Bibliographic Details
Main Authors: Johansen Taber KA, Dickinson BD
Format: Article
Language:English
Published: Dove Medical Press 2015-01-01
Series:The Application of Clinical Genetics
Online Access:http://www.dovepress.com/genomic-based-tools-for-the-risk-assessment-management-and-prevention--peer-reviewed-article-TACG
id doaj-47555903199c4edd8c0488591eaee93b
record_format Article
spelling doaj-47555903199c4edd8c0488591eaee93b2020-11-24T22:46:36ZengDove Medical PressThe Application of Clinical Genetics1178-704X2015-01-012015default1819860Genomic-based tools for the risk assessment, management, and prevention of type 2 diabetesJohansen Taber KADickinson BD Katherine A Johansen Taber, Barry D DickinsonDepartment of Science and Biotechnology, American Medical Association, Chicago, IL, USAAbstract: Type 2 diabetes (T2D) is a common and serious disorder and is a significant risk factor for the development of cardiovascular disease, neuropathy, nephropathy, retinopathy, periodontal disease, and foot ulcers and amputations. The burden of disease associated with T2D has led to an emphasis on early identification of the millions of individuals at high risk so that management and intervention strategies can be effectively implemented before disease progression begins. With increasing knowledge about the genetic basis of T2D, several genomic-based strategies have been tested for their ability to improve risk assessment, management and prevention. Genetic risk scores have been developed with the intent to more accurately identify those at risk for T2D and to potentially improve motivation and adherence to lifestyle modification programs. In addition, evidence is building that oral antihyperglycemic medications are subject to pharmacogenomic variation in a substantial number of patients, suggesting genomics may soon play a role in determining the most effective therapies. T2D is a complex disease that affects individuals differently, and risk prediction and treatment may be challenging for health care providers. Genomic approaches hold promise for their potential to improve risk prediction and tailor management for individual patients and to contribute to better health outcomes for those with T2D.Keywords: diabetes, genomic, risk prediction, managementhttp://www.dovepress.com/genomic-based-tools-for-the-risk-assessment-management-and-prevention--peer-reviewed-article-TACG
collection DOAJ
language English
format Article
sources DOAJ
author Johansen Taber KA
Dickinson BD
spellingShingle Johansen Taber KA
Dickinson BD
Genomic-based tools for the risk assessment, management, and prevention of type 2 diabetes
The Application of Clinical Genetics
author_facet Johansen Taber KA
Dickinson BD
author_sort Johansen Taber KA
title Genomic-based tools for the risk assessment, management, and prevention of type 2 diabetes
title_short Genomic-based tools for the risk assessment, management, and prevention of type 2 diabetes
title_full Genomic-based tools for the risk assessment, management, and prevention of type 2 diabetes
title_fullStr Genomic-based tools for the risk assessment, management, and prevention of type 2 diabetes
title_full_unstemmed Genomic-based tools for the risk assessment, management, and prevention of type 2 diabetes
title_sort genomic-based tools for the risk assessment, management, and prevention of type 2 diabetes
publisher Dove Medical Press
series The Application of Clinical Genetics
issn 1178-704X
publishDate 2015-01-01
description Katherine A Johansen Taber, Barry D DickinsonDepartment of Science and Biotechnology, American Medical Association, Chicago, IL, USAAbstract: Type 2 diabetes (T2D) is a common and serious disorder and is a significant risk factor for the development of cardiovascular disease, neuropathy, nephropathy, retinopathy, periodontal disease, and foot ulcers and amputations. The burden of disease associated with T2D has led to an emphasis on early identification of the millions of individuals at high risk so that management and intervention strategies can be effectively implemented before disease progression begins. With increasing knowledge about the genetic basis of T2D, several genomic-based strategies have been tested for their ability to improve risk assessment, management and prevention. Genetic risk scores have been developed with the intent to more accurately identify those at risk for T2D and to potentially improve motivation and adherence to lifestyle modification programs. In addition, evidence is building that oral antihyperglycemic medications are subject to pharmacogenomic variation in a substantial number of patients, suggesting genomics may soon play a role in determining the most effective therapies. T2D is a complex disease that affects individuals differently, and risk prediction and treatment may be challenging for health care providers. Genomic approaches hold promise for their potential to improve risk prediction and tailor management for individual patients and to contribute to better health outcomes for those with T2D.Keywords: diabetes, genomic, risk prediction, management
url http://www.dovepress.com/genomic-based-tools-for-the-risk-assessment-management-and-prevention--peer-reviewed-article-TACG
work_keys_str_mv AT johansentaberka genomicbasedtoolsfortheriskassessmentmanagementandpreventionoftype2diabetes
AT dickinsonbd genomicbasedtoolsfortheriskassessmentmanagementandpreventionoftype2diabetes
_version_ 1725684622559281152